Analyst Ratings for Karyopharm Therapeutics (KPTI)
KPTI Rating Summary
KPTI Price Target Summary
- Highest: $28.00 (Rodman & Renshaw)
- Lowest: $3.00 (Baird)
- Average: $11.67
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$11.67 (+530.6%)
* Over Last 12-Mos
Rating Score: 6.1 / 10
Percentile Rank: 65%
Avg. $ Target:
$11.67 (+530.6%)
* Over Last 12-Mos
Rating Score: 6.1 / 10
Percentile Rank: 65%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 7/31/2026 | H.C. Wainwright | Robert Burns | Downgrade | Neutral (Buy) |
N/A (N/A) |
7.01 (1.85) |
-73.61% | Details |
| 7/31/2026 | Baird | Colleen Kusy | Downgrade | Neutral (Outperform) |
3.00 (15.00) |
6.86 (1.85) |
-73.03% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
